The effects of N-terminal insertion into VSV-G of an scFv peptide

Virology Journal

Volumn 3, Issue , 2006, Pages

  Dreja, Hanna ^a   Piechaczyk, Marc ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS G PROTEIN; VIRUS PROTEIN; VIRUS VECTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DESMOSOME; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; NONHUMAN; PROTEIN ENGINEERING; PROTEIN MODIFICATION; RETROVIRUS; VIRUS TRANSMISSION;

ANIMALS; CELL LINE; DNA, RECOMBINANT; GENE TRANSFER TECHNIQUES; GENES, MHC CLASS I; HELA CELLS; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MEMBRANE GLYCOPROTEINS; MICE; RECOMBINANT FUSION PROTEINS; VIRAL ENVELOPE PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1; VESICULAR STOMATITIS VIRUS;

EID: 33748774154     PISSN: 1743422X     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-3-69     Document Type: Article

References (36)

1. Lundstrom K: Latest development in viral vectors for gene therapy. Trends Biotechnol 2003, 21:117-122.
2. Gould DJ, Favorov P: Vectors for the treatment of autoimmune disease. Gene Ther 2003, 10:912-927.
3. Sinn PL, Sauter SL, McCray PBJ: Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors - design, biosafety, and production. Gene Ther 2005, 12:1089-1098.
4. Sandrin V, Russell SJ, Cosset FL: Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol 2003, 281:137-178.
5. Lavillette D, Russell SJ, Cosset FL: Retargeting gene delivery using surface-engineered retroviral vector particles. Curr Opin Biotechnol 2001, 12:461-466.
6. Karavanas G, Marin M, Salmons B, Gunzburg WH, Piechaczyk M: Cell targeting by murine retroviral vectors. Crit Rev Oncol Hematol 1998, 28:7-30.
7. Zhao Y, Zhu L, Lee S, Li L, Chang E, Soong NW, Douer D, Anderson WF: Identification of the block in targeted retroviral-mediated gene transfer. Proc Natl Acad Sci U S A 1999, 96:4005-4010.
8. Benedict CA, Tun RY, Rubinstein DB, Guillaume T, Cannon PM, Anderson WF: Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion. Hum Gene Ther 1999, 10:545-557.
9. Karavanas G, Marin M, Bachrach E, Papavassiliou AG, Piechaczyk M: The insertion of an anti-MHC I ScFv into the N-terminus of an ecotropic MLV glycoprotein does not alter its fusiogenic potential on murine cells. Virus Res 2002, 83:57-69.
10. Hatziioannou T, Delahaye E, Martin F, Russell SJ, Cosset FL: Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther 1999, 10:1533-1544.
11. Morizono K, Bristol G, Xie YM, Kung SK, Chen IS: Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol 2001, 75:8016-8020.
12. Morizono K, Xie Y, Ringpis GE, Johnson M, Nassanian H, Lee B, Wu L, Chen IS: Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 2005, 11:346-352.
13. Aires da Silva F, Costa MJ, Corte-Real S, Goncalves J: Cell type-specific targeting with sindbis pseudotyped lentiviral vectors displaying anti-CCR5 single-chain antibodies. Hum Gene Ther 2005, 16:223-234.
14. Lu X, Humeau L, Slepushkin V, Binder G, Yu Q, Slepushkina T, Chen Z, Merling R, Davis B, Chang YN, Dropulic B: Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med 2004, 6:963-973.
15. Quinonez R, Sutton RE: Lentiviral vectors for gene delivery into cells. DNA Cell Biol 2002, 21:937-951.
16. Coil DA, Miller AD: Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J Virol 2004, 78:10920-10926.
17. Guibinga GH, Hall FL, Gordon EM, Ruoslahti E, Friedmann T: Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype. Mol Ther 2004, 9:76-84.
18. Li Y, Drone C, Sat E, Ghosh HP: Mutational analysis of the vesicular stomatitis virus glycoprotein G for membrane fusion domains. J Virol 1993, 67:4070-4077.
19. Schlehuber LD, Rose JK: Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein. J Virol 2004, 78:5079-5087.
20. Yu JH, Schaffer DV: Selection of novel vesicular stomatitis virus glycoprotein variants from a peptide insertion library for enhanced purification of retroviral and lentiviral vectors. J Virol 2006, 80:3285-3292.
21. Roux P, Jeanteur P, Piechaczyk M: A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc Natl Acad Sci U S A 1989, 86:9079-9083.
22. Etienne-Julan M, Roux P, Carillo S, Jeanteur P, Piechaczyk M: The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J Gen Virol 1992, 73 ( Pt 12):3251-3255.
23. Marin M, Noel D, Valsesia-Wittman S, Brockly F, Etienne-Julan M, Russell S, Cosset FL, Piechaczyk M: Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J Virol 1996, 70:2957-2962.
24. Rebai N, Malissen B: Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. Tissue Antigens 1983, 22:107-117.
25. Briant L, Benkirane M, Girard M, Hirn M, Iosef C, Devaux C: Inhibition of human immunodeficiency virus type 1 production in infected peripheral blood mononuclear cells by human leukocyte antigen class I-specific antibodies: evidence for a novel antiviral mechanism. J Virol 1996, 70:5213-5220.
26. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G: Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989, 341:544-546.
27. Russell SJ, Hawkins RE, Winter G: Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 1993, 21:1081-1085.
28. Coll JM: The glycoprotein G of rhabdoviruses. Arch Virol 1995, 140:827-851.
29. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, D. T: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
30. Schlegel R, Sue TT, Willingham MC, Pastan I: Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-bidning site? Cell 1983, 32:639-646.
31. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK: High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995, 69:7430-7436.
32. Scherer WF, Syverton JT, Gey GO: Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med 1953, 97:695-710.
33. Graham FL, Smiley J, Russell WC, Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977, 36:59-74.
34. Gluzman Y: SV40-transformed simian cells support the replication of early SV40 mutants. Cell 1981, 23:175-182.
35. Lander MR, Chattopadhyay SK: A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses. J Virol 1984, 52:695-698.
36. Sambrook J, Fritsch E, Maniatis T: Molecular cloning: a laboratory manual. In Cold Spring Harbor Laboratory Press 2nd edition. Cold Spring Harbor, Cold Spring Harbor Laboratory Press; 1989.